PNB ready to enter Phase III development with PNB01 in Major Depression
Advertisement
Pharmaneuroboost (PNB) reported that it received clearance from the Institutional Review Board (IRB) to initiate its first phase III study with PNB01 in the USA.
“We are particularly excited to have passed this first hurdle on our way to start phase III with PNB01 in the USA, which is a rather unique achievement for a small Flemish biotech company”, says Chief Executive Officer Erik Buntinx, MD. “PNB’s experienced management team has been preparing this phase III program for a long time, and we are proud to reach this important milestone, having met all organizational, regulatory, financial and also ethical requirements”.
“We expect to obtain similar approvals in Germany and Canada in the very near future”, says Philippe Lemmens, PhD, Clinical Study Director. “Previously, competent authorities already agreed with the clinical trial protocol design, and so we expect to start recruiting patients in the coming month, pending their final approval”.
PNB01 is the first of two front-running, late stage proprietary projects of PNB.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Alternatives to the use of transgenic animals - Experts evaluated the current status of the use of genetically modified animals in research and discussed alternative methods

Resistant bacteria can remain in the body for years - “These patients not only repeatedly become ill themselves, they also act as a source of infection for other people”
Amercian Peptide Company enhances global customer support capabilities
